STOCK TITAN

Shattuck Labs (STTK) SEC Filings

STTK NASDAQ

Shattuck Labs, Inc. filings document the regulatory disclosures of a clinical-stage biotechnology company developing DR3-blocking antibodies for inflammatory and immune-mediated diseases. Its 8-K reports cover operating results, financial condition, clinical-program updates for SL-325, material agreements, and capital-structure matters involving its Nasdaq-listed common stock.

Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, stockholder proposal deadlines, board composition changes, and executive-compensation or equity-award topics. Registration and offering-related disclosures include common stock financing arrangements, Form S-3 materials, and at-the-market offering mechanics.

Rhea-AI Summary

Shattuck Labs, Inc. (STTK) reports 14,347,736 common shares as beneficially owned by T. Rowe Price Investment Management, Inc., equal to 14.3% of the class. The manager reports sole voting power over 14,319,457 shares and sole dispositive power over 14,347,736 shares. It states that it is not custodian of client assets; clients or their custodians or trustee banks have the right to receive dividends and sale proceeds, and clients hold ultimate power to direct their receipt. The manager expressly denies that the report is an admission of beneficial ownership. T. Rowe Price Small-Cap Stock Fund has an interest in 3,487,102 shares, or 5.5% of the class.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
ownership
-
Rhea-AI Summary

Shattuck Labs, Inc. (STTK) reported that Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin each beneficially owned 5,000,033 shares, or 4.92%, as of September 30, 2026, with shared voting and dispositive power.

The reported amount includes 1,293,299 pre-funded warrants exercisable for common stock. Exercise is limited when it would cause the holders’ collective beneficial ownership to exceed 9.99% of common stock outstanding after exercise. The percentage calculation used 100,363,253 common shares outstanding as of August 7, 2026, plus the warrants, for a stated denominator of 101,656,552 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
ownership
-
Rhea-AI Summary

Shattuck Labs, Inc. (STTK) reported a third-quarter net loss of $25.2 million, compared with $10.1 million a year earlier; its nine-month net loss was $55.1 million versus $36.2 million. For the nine months, research and development expense was $44.2 million compared with $26.2 million, and net cash used in operating activities was $41.1 million versus $31.4 million.

Cash, cash equivalents and short-term investments totaled $196.3 million as of September 30, 2026; management believes this is sufficient to fund projected operations for at least the next 12 months following issuance of the financial statements. Shattuck initiated its Phase 2b Crohn’s disease trial of SL-325 in the third quarter and expects induction data in the first half of 2028. It expects to start an SL-325 Phase 2b hidradenitis suppurativa trial in the fourth quarter of 2026, with primary-phase data expected in the first half of 2028. In Phase 1, the company reported only mild, Grade 1 treatment-related adverse events in 12 participants and treatment-emergent anti-drug antibodies in 3.7% of participants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.82%
Tags
quarterly report
Rhea-AI Summary

Shattuck Labs, Inc. (STTK) reported a third-quarter 2026 net loss of $25.2 million, or $0.14 per basic and diluted share, compared with a $10.1 million net loss in the year-earlier quarter. Research and development expenses were $21.6 million versus $7.6 million, and general and administrative expenses were $5.5 million versus $4.1 million.

Cash and cash equivalents and short-term investments totaled $196.3 million as of September 30, 2026. The company expects these resources to fund operations into 2029 under current plans, excluding additional capital, business-development proceeds and certain clinical-development costs. Shattuck initiated its SL-325 Phase 2b Crohn’s disease trial, with 12-week induction data expected in the first half of 2028. Initiation of its SL-325 hidradenitis suppurativa Phase 2 trial is expected in the fourth quarter of 2026, with data expected in the first half of 2028. The company expects to initiate an SL-846 Phase 1 trial and report initial data in 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.82%
Tags
current report
-
Rhea-AI Summary

Shattuck Labs, Inc. (STTK) is the issuer whose common stock BlackRock, Inc. reported beneficial ownership of 5,339,458 shares, or 5.3% of the class, as of September 30, 2026. BlackRock reported sole voting power over 5,221,737 shares and sole dispositive power over 5,339,458 shares; shared voting and dispositive power were both zero.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
ownership
-
Rhea-AI Summary

T. Rowe Price Investment Management, Inc. reports beneficial ownership of 13,432,540 shares of SHATTUCK LABS INC common stock on a Schedule 13G/A (Amendment No. 2). This position represents 15.3% of the outstanding common stock, all with sole dispositive power and 13,391,090 shares with sole voting power.

The firm states that voting and economic benefits ultimately belong to its underlying clients, who may revoke delegated authority. The T. Rowe Price Small-Cap Value Fund is identified as holding 3,565,344 shares, or 5.6% of the class. T. Rowe Price Investment Management expressly denies beneficial ownership in its own right.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
ownership
Rhea-AI Summary

Shattuck Labs, Inc. reported second quarter 2026 results and development updates for its DR3-targeted antibody pipeline. The company had $208.3 million in cash, cash equivalents and short-term investments as of June 30, 2026, supported by an $86.2 million underwritten offering and $57.1 million of warrant exercise proceeds, and expects this capital to fund operations into 2029.

For the quarter, Shattuck recorded no revenue, research and development expenses of $11.7 million, general and administrative expenses of $4.5 million, and a net loss of $15.2 million, or $0.12 per share. Phase 1 data for lead antibody SL-325 showed a favorable safety and immunogenicity profile and durable DR3 blockade, with a Phase 2b Crohn’s disease trial expected to start in the third quarter of 2026. Bispecific candidate SL-846 is in IND-enabling GLP toxicology studies, with initial Phase 1 data planned for 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
current report
-
Rhea-AI Summary

Shattuck Labs, Inc. is a clinical-stage biotechnology company developing DR3-blocking monoclonal and bispecific antibodies for inflammatory and immune‑mediated diseases. The company’s lead program, SL‑325, completed a Phase 1 trial in healthy volunteers, showing a favorable safety profile, dose‑proportional pharmacokinetics, and durable receptor occupancy exceeding 76 days at doses of 1 mg/kg or higher. Management plans to start RECEPTIVE‑CD1, a Phase 2b trial in Crohn’s disease, in the third quarter of 2026, with induction data expected in the first half of 2028. A bispecific candidate, SL‑846, targeting DR3 and IL‑23 receptors, is in non‑human primate toxicology studies, with Phase 1 data planned for 2027.

For the six months ended June 30, 2026, Shattuck reported no revenue and a net loss of $29.9 million compared with $26.2 million a year earlier, driven mainly by higher research and development spending of $22.6 million. General and administrative expenses were $9.1 million. Cash, cash equivalents and short‑term investments totaled $208.3 million, supported by recent equity and warrant financings, and management believes this balance will fund operations for at least twelve months after the financial statements’ issuance date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
quarterly report
-
Rhea-AI Summary

Redmile Group, LLC, Jeremy C. Green and Redmile Biopharma Investments II, L.P. updated their ownership report for Shattuck Labs, Inc. common stock. They may be deemed to beneficially own 10,019,421 shares, representing 9.9% of the class, with shared voting and dispositive power over all of these shares. Redmile Biopharma Investments II, L.P. is reported with 8,125,342 shares, or 8.1% of the class.

The position as of July 17, 2026 comprises 5,233,076 shares of common stock (including 3,338,997 shares held directly by RBI II) plus 4,786,345 shares issuable upon exercise of pre-funded warrants, the maximum permitted under a 9.99% Beneficial Ownership Limitation. The Redmile funds hold pre-funded warrants for up to 10,943,951 shares, including 5,647,258 underlying shares at RBI II, and 146,086 shares subject to stock options exercisable within 60 days that are held by a former director as nominee for Redmile. Between July 10 and July 17, 2026, the group executed multiple open market sales and on July 17 used approximately $1,000,000 of working capital to purchase 143,808 shares at a weighted average price of about $7.46 per share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.43%
Tags
ownership
Rhea-AI Summary

Shattuck Labs Chief Technical Officer Abhinav A. Shukla reported option exercises and a small share sale in Common Stock. He exercised options to acquire 12,563 shares at $3.57 per share in two transactions and now holds 98,533 Common shares directly.

Shukla also sold 410 shares of Common Stock at a weighted average price of $7.01 per share, with individual sale prices ranging from $7.00 to $7.03. The sale was made under a pre-arranged Rule 10b5-1 trading plan designed to fund option exercise costs and related tax withholding. Following these transactions, he also holds 14,140 stock options with a $3.57 exercise price, expiring on January 25, 2033.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.23%
Tags
insider

FAQ

How many Shattuck Labs (STTK) SEC filings are available on StockTitan?

StockTitan tracks 93 SEC filings for Shattuck Labs (STTK), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Shattuck Labs (STTK)?

The most recent SEC filing for Shattuck Labs (STTK) was filed on November 16, 2026.